```html

Donor‑Derived Infection (Post‑Transplant) – A Patient‑Focused Medical Guide

Overview

Donor‑derived infection (DDI) refers to any infectious organism that is transmitted from an organ or tissue donor to the recipient during transplantation. These infections can appear days, weeks, or even months after the procedure and may involve bacteria, viruses, fungi, or parasites.

Who it affects: Anyone who receives a solid‑organ (kidney, liver, heart, lung, pancreas) or hematopoietic stem cell transplant (HSCT) is at risk. The condition is most frequently reported in:

• Kidney transplant recipients (≈30‑40% of reported DDIs)
• Liver transplant recipients (≈25%)
• HSCT patients (≈20%)

Prevalence: Although overall transplant‑related infection rates are high, true donor‑derived infections are relatively rare, accounting for 0.5‑2% of all post‑transplant infections.<sup>[1] CDC, 2022</sup> The exact number varies by organ type and screening practices. For example, in the United States between 2008‑2017, the Organ Procurement and Transplantation Network (OPTN) documented 161 confirmed DDIs out of >380,000 transplants, a rate of 0.04% per transplant.<sup>[2] OPTN Annual Report</sup>

Symptoms

Because DDIs can be caused by many different pathogens, the clinical picture is broad. Below is a consolidated list of the most common symptoms, grouped by organ system, with brief descriptions.

General / Constitutional

• Fever & chills – Persistent temperature >38°C (100.4°F); may be low‑grade in immunosuppressed patients.
• Fatigue & malaise – Unexplained weakness that does not improve with rest.
• Weight loss – Unintentional loss >5% of body weight over 1‑2 months.

Respiratory

• Cough (dry or productive)
• Shortness of breath or rapid breathing
• Chest pain, especially pleuritic pain
• Wheezing or stridor (possible in fungal or viral infections)

Gastrointestinal

• Nausea, vomiting, or loss of appetite
• Diarrhea (may be watery, bloody, or contain mucus)
• Abdominal pain or tenderness

Urinary Tract

• Dysuria, frequency, urgency
• Flank pain or costovertebral angle tenderness
• Cloudy or foul‑smelling urine

Neurologic

• Headache (often severe or refractory to usual analgesics)
• Altered mental status, confusion, or lethargy
• Seizures
• Focal deficits (weakness, vision changes)

Skin & Soft Tissue

• Rash (maculopapular, vesicular, or pustular)
• Ulcerations, cellulitis, or necrotic lesions
• Painful nodules (may suggest mycobacterial infection)

Cardiovascular

• Palpitations or new arrhythmias
• Chest discomfort unrelated to graft rejection
• Signs of sepsis (hypotension, tachycardia)

Because transplant patients are immunosuppressed, infections may present atypically—e.g., minimal fever despite bacteremia. Any new or unexplained symptom after transplantation should prompt evaluation.

Causes and Risk Factors

DDIs are the result of organisms that either:

• Reside in the donor organ at the time of procurement.
• Are present in the donor’s bloodstream (often asymptomatic).
• Are introduced during preservation, transport, or the surgical procedure.

Common Pathogens

Pathogen Type	Typical Sources	Typical Post‑Transplant Presentation
Viruses (CMV, EBV, HBV, HCV, HIV, SARS‑CoV‑2)	Donor viremia, latent infection in organ tissue	Fever, hepatitis, pneumonitis, PTLD (post‑transplant lymphoproliferative disorder)
Bacteria (Gram‑negative bacilli, Staphylococcus aureus, Listeria, Mycobacterium spp.)	Donor bacteremia, contaminated preservation solution	Sepsis, wound infection, urinary tract infection
Fungi (Candida, Aspergillus, Cryptococcus, Endemic dimorphic fungi)	Donor colonisation, environmental exposure during retrieval	Pulmonary infiltrates, meningitis, disseminated disease
Parasites (Toxoplasma gondii, Trypanosoma cruzi, Strongyloides)	Donor endemic exposure, latent tissue cysts	Myocarditis, encephalitis, gastrointestinal disease

Key Risk Factors

• Donor‑related factors
  • Recent infection or colonisation not detected during screening.
  • Travel or residence in endemic areas for certain parasites or fungi.
  • Positive serology for CMV, EBV, HBV, or HCV without appropriate prophylaxis.
• Recipient‑related factors
  • High level of immunosuppression (e.g., anti‑thymocyte globulin, high‑dose steroids).
  • Prior history of opportunistic infection.
  • Co‑existing comorbidities such as diabetes, chronic lung disease, or renal insufficiency.
• Procedural factors
  • Prolonged cold ischemia time (organ kept on ice >12‑18 h).
  • Contamination of preservation solution or surgical instruments.
  • Use of marginal or “extended criteria” donors without thorough screening.

Diagnosis

Timely identification of a DDI requires a high index of suspicion, especially when symptoms develop early (<30 days) after transplant or when the clinical picture does not match typical rejection patterns.

Initial Evaluation

• Comprehensive history – donor’s infectious disease screening results, travel history, and any recent infections.
• Focused physical examination – looking for organ‑specific signs (e.g., skin lesions, lung findings).
• Baseline laboratory tests – CBC with differential, CMP, CRP/ESR, and cultures (blood, urine, sputum).

Targeted Diagnostic Tests

1. Microbiological cultures – blood, urine, wound, bronchoalveolar lavage (BAL) fluid.
2. Polymerase chain reaction (PCR) panels – rapid detection of viral DNA/RNA (CMV, EBV, BK virus, SARS‑CoV‑2).
3. Serologic testing – donor‑recipient paired serology for CMV, EBV, hepatitis viruses, HIV, Toxoplasma.
4. Imaging – chest X‑ray or CT for pulmonary infections; abdominal ultrasound/CT for intra‑abdominal or hepatic disease.
5. Histopathology – biopsy of graft tissue when infection vs. rejection is unclear; special stains (GMS, PAS) for fungi, acid‑fast for mycobacteria.
6. Next‑generation sequencing (NGS) – emerging tool for detecting rare or unculturable pathogens, especially in culture‑negative sepsis.

Diagnostic Criteria

The United Network for Organ Sharing (UNOS) and CDC define a DDI when:

• A pathogen is identified in the recipient, and
• Evidence indicates the donor was the source (e.g., identical strain typing, temporal relationship, absence of other exposure).

Treatment Options

Treatment is individualized based on the organism, severity of illness, graft function, and the recipient’s immunosuppressive regimen.

Antimicrobial Therapy

Pathogen	First‑Line Therapy	Typical Duration
CMV (viremia or disease)	IV ganciclovir 5 mg/kg q12h or oral valganciclovir 900 mg BID	2‑4 weeks, then maintenance until cleared
EBV (PTLD)	Reduce immunosuppression + rituximab; antiviral therapy (acyclovir) is adjunct	Varies; often months
HBV/HCV	HBV – entecavir/tenofovir; HCV – direct‑acting antivirals (sofosbuvir/velpatasvir)	HBV: indefinite; HCV: 12 weeks
Gram‑negative bacteremia	Extended‑spectrum carbapenem (e.g., meropenem) +/‑ aminoglycoside	7‑14 days, longer if end‑organ involvement
Staphylococcus aureus (MRSA)	IV vancomycin (target trough 15‑20 µg/mL)	4‑6 weeks for deep infection
Candida spp.	Echinocandin (caspofungin 70 mg loading, then 50 mg daily)	≥2 weeks after clearance of blood cultures
Aspergillus spp.	Voriconazole (6 mg/kg q12h loading, then 4 mg/kg q12h)	≥6‑12 weeks
Toxoplasma gondii	Pyrimethamine + sulfadiazine + leucovorin	6‑12 weeks acute, then prophylaxis

Adjustment of Immunosuppression

• Temporarily reduce or hold antimetabolites (mycophenolate, azathioprine) to allow immune clearance.
• Maintain calcineurin inhibitors at the lowest effective level to protect the graft while avoiding rejection.
• Close monitoring of drug levels is essential.

Surgical & Procedural Interventions

• Drainage of abscesses or infected fluid collections.
• Debridement of infected soft‑tissue or prosthetic material.
• In severe graft infection, organ explantation may be unavoidable (rare, usually a last resort).

Supportive Care & Lifestyle Measures

• Hydration, nutritional support, and fever control (acetaminophen is preferred).
• Close monitoring of renal and hepatic function while on potentially nephrotoxic or hepatotoxic drugs.
• Vaccinations (e.g., influenza, pneumococcal) once the infection resolves and immunosuppression is stable.

Living with Donor‑Derived Infection (Post‑Transplant)

Long‑term management focuses on infection control, graft health, and overall well‑being.

Medication Adherence

• Take all antimicrobial and immunosuppressive drugs exactly as prescribed.
• Use a pill organizer or smartphone reminders.
• Report any side effects promptly; dose adjustments may be needed.

Regular Follow‑Up

• Clinic visits at least monthly for the first 6 months, then every 3‑6 months.
• Routine labs: CBC, CMP, viral PCR (CMV, EBV), drug‑level monitoring.
• Imaging as directed (e.g., chest X‑ray every 3‑6 months if pulmonary infection was present).

Lifestyle Strategies

• Infection‑prevention hygiene: frequent handwashing, avoid crowds during community outbreaks, wear masks in high‑risk settings.
• Nutrition: balanced diet rich in protein; limit raw or undercooked foods that may harbor parasites (e.g., unpasteurized dairy, rare meats).
• Exercise: moderate activity as tolerated; avoid contact sports that could cause graft injury.
• Stress management: adequate sleep, mindfulness, or counseling to reduce immunosuppression‑related mood disturbances.

Monitoring for Recurrence

Even after successful treatment, some pathogens (CMV, EBV, Toxoplasma) may reactivate. Keep a symptom diary and alert your team if you notice fever, new rashes, or organ‑specific changes.

Prevention

Most DDIs can be avoided through rigorous donor screening, recipient prophylaxis, and careful peri‑operative practices.

Donor Screening Protocols

• Serologic tests for CMV, EBV, HBV, HCV, HIV, toxoplasma, and syphilis.
• Nucleic‑acid testing (NAT) for HIV, HBV, HCV, and emerging viruses (e.g., SARS‑CoV‑2).
• Geographic risk assessment for endemic fungi (Histoplasma, Coccidioides) and parasites.
• Culture of preservation fluids and organ cannulation lines.

Recipient Prophylaxis

• Antiviral prophylaxis – e.g., valganciclovir for CMV‑negative recipients of CMV‑positive donors (15–21 days pre‑transplant to 3‑6 months post‑transplant).
• Antibacterial prophylaxis – usually a fluoroquinolone for the first month after kidney transplant.
• Antifungal prophylaxis – echinocandin or azole for high‑risk lung or liver recipients.
• Parasite prophylaxis – TMP‑SMX for Toxoplasma and Pneumocystis jirovecii, typically 6‑12 months.

Peri‑operative Measures

• Strict aseptic technique in the operating room.
• Use of sterile preservation solutions; discard if clouded or contaminated.
• Rapid implantation to minimize cold ischemia time.
• Post‑operative surveillance cultures when donor infection is suspected.

Complications

If a DDI is not recognized or adequately treated, complications can be severe and life‑threatening.

• Sepsis and septic shock – multi‑organ failure, high mortality (30‑50% in severe cases).
• Graft loss – infection can directly damage the organ (e.g., CMV hepatitis) or trigger rejection.
• Post‑transplant lymphoproliferative disorder (PTLD) – driven by EBV; may present as lymphoma.
• Chronic organ dysfunction – e.g., interstitial lung disease after fungal infection.
• Secondary opportunistic infections – due to further immune compromise during treatment.
• Medication toxicities – nephrotoxic antivirals (ganciclovir), hepatotoxic antifungals (voriconazole).

When to Seek Emergency Care

---

References:
[1] Centers for Disease Control and Prevention. “Transplant‑Associated Infections.” Updated 2022.
[2] Organ Procurement and Transplantation Network (OPTN) Annual Report 2020‑2021.
[3] Mayo Clinic. “Donor‑Derived Infection after Transplant.” 2023.
[4] Cleveland Clinic. “Management of CMV in Transplant Recipients.” 2022.
[5] NIH National Library of Medicine. “Guidelines for Prevention of Opportunistic Infections in Transplant Recipients.” 2021.

```